MSB 2.33% $4.40 mesoblast limited

Multisystem Inflammatory Syndrome in Children (MIS-C), page-2

  1. 35 Posts.
    lightbulb Created with Sketch. 132
    ‘This intermediate-size expanded access protocol plans to treat approximately 50 children or adolescents, male and female, with MIS-C associated with COVID-19. Participants who are 2 months to 17 years of age, inclusive, will be enrolled at multiple clinical sites across the United States.’
    ‘The objectives of this intermediate-size expanded access protocol are to assess the safety and efficacy of remestemcel-L in participants with MIS-C associated with COVID-19.’

watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Mkt cap ! $2.571B
Open High Low Value Volume
$4.27 $4.48 $4.23 $31.89M 7.270M

Buyers (Bids)

No. Vol. Price($)
11 40300 $4.40

Sellers (Offers)

Price($) Vol. No.
$4.42 16656 2
View Market Depth
Last trade - 16.10pm 07/08/2020 (20 minute delay) ?
0.100 ( 3.17 %)
Open High Low Volume
$4.28 $4.47 $4.24 1560205
Last updated 15.59pm 07/08/2020 (live) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.